{"id":"W2495043549","doi":"10.1016/j.clbc.2016.07.008","title":"Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5","year":2016,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Trastuzumab; Docetaxel; Epirubicin; Breast cancer; Internal medicine; Oncology; Cyclophosphamide; Neoadjuvant therapy; Regimen; Ejection fraction; Chemotherapy; Cancer; Heart failure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001111328,0.0008869476,0.001352731,0.0000816189,0.0009729713,0.00006820552,0.0006041555,0.0004400126,0.0001579377],"category_scores_gemma":[0.0001072463,0.0004534006,0.0004484283,0.00042896,0.001910713,0.00008231254,0.0002289912,0.0004464573,0.000001577929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005236024,"about_ca_system_score_gemma":0.001869752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004371937,"about_ca_topic_score_gemma":0.003706553,"domain_scores_codex":[0.9945683,0.0006896631,0.001099579,0.001761742,0.0007427976,0.00113793],"domain_scores_gemma":[0.9954912,0.0008661795,0.0009025335,0.0008463259,0.001548215,0.0003455101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5080971,0.003385466,0.004174597,0.00005270925,0.001608944,0.00001397738,0.0004037849,0.00002010074,0.02259728,0.00004203281,0.0007367496,0.4588673],"study_design_scores_gemma":[0.6547222,0.08674297,0.181667,0.003028611,0.001012231,0.0006336707,0.002100561,0.00004191005,0.05686153,0.0003759747,0.01040684,0.002406576],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9598321,0.003829611,0.001147558,0.01118437,0.0004866347,0.006948575,0.01648527,0.00004349953,0.00004238547],"genre_scores_gemma":[0.9715536,0.01694656,0.0002243322,0.001293187,0.0007947111,0.007931045,0.0002130526,0.0001695283,0.0008739549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4564607,"threshold_uncertainty_score":0.9997918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02857434050699278,"score_gpt":0.3893923807055655,"score_spread":0.3608180401985728,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}